Sorrento to begin Phase I trial of oral Covid-19 treatment

Sorrento Therapeutics is set to commence a Phase I clinical trial of its oral therapy, STI-1558, for Covid-19 in China.

The latest development comes after the company received approval from the China National Medical Products Administration (NMPA) for its investigational new drug (IND) application for STI-1558.